Children's Hospital, Zhejiang University School of Medicine
浙江大学医学院附属儿童医院
Listed for 21 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Children's Hospital, Zhejiang University School of Medicine
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Hepatoblastoma肝母细胞瘤1 paper led
- Osteosarcoma骨肉瘤5 papers led
- Neuroblastoma神经母细胞瘤7 papers led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病5 papers led
- Aplastic anaemia再生障碍性贫血2 papers led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症8 papers led
- Haemophilia A血友病 A0 papers led
- Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
- Myasthenia gravis重症肌无力1 paper led1 open trial led
- Biliary atresia胆道闭锁2 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
- Spinal muscular atrophy脊髓性肌萎缩症2 papers led
- Fabry disease法布雷病2 papers led1 open trial led
- Duchenne muscular dystrophy杜氏肌营养不良0 papers led
- Alport syndromeAlport 综合征0 papers led
- IgA nephropathyIgA 肾病7 papers led4 open trials led
- Niemann–Pick disease type C尼曼-匹克病 C 型0 papers led
- Congenital diaphragmatic hernia先天性膈疝0 papers led
- Hirschsprung disease先天性巨结肠4 papers led
- Leber hereditary optic neuropathyLeber 遗传性视神经病变4 papers led
- Majeed syndromeMajeed 综合征1 paper led
Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Ewing sarcoma, Multiple myeloma, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Moyamoya disease, Wilson disease, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Pompe disease, Behçet disease, Gaucher disease, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, NGLY1 deficiency, ISG15 deficiency.
Cancer
Hepatoblastoma
肝母细胞瘤Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Hangzhou for hepatoblastoma88 hospitals in China for hepatoblastoma
No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Osteosarcoma
骨肉瘤Led 5 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
22 hospitals in Hangzhou for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led5
- Survival profiles and associated factors for overall and cancer specific survival in patients with chondroblast and fibroblastic osteosarcoma.
- Leveraging diverse cell death patterns in osteosarcoma patients and identification of the function of FADS2 in osteosarcoma cells.
- Predicting metastasis at initial diagnosis and radiotherapy effectiveness in patients with metastatic osteosarcoma.
- Identification of LARS as an essential gene for osteosarcoma proliferation through large-Scale CRISPR-Cas9 screening database and experimental verification.
- Advances in targeted therapy for osteosarcoma based on molecular classification.
Cancer
Neuroblastoma
神经母细胞瘤Led 7 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.6%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Hangzhou for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led7
- Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors.
- Disruption of the KLHL37-N-Myc complex restores N-Myc degradation and arrests neuroblastoma growth in mouse models.
- Author(s)' Reply: Is MYCN Overexpression Associated With Poor Outcome in MYCN Non-Amplified Neuroblastomas?
- Perioperative complication incidence and risk factors for retroperitoneal neuroblastoma in children: analysis of 571 patients.
- Current vaccination status and safety of children with peripheral neuroblastoma in the real-world.
- Rapid detection of telomerase expression of neuroblastoma in paraffin-embedded tissue: combination of in situ hybridisation and quantitative PCR.
- Prominent Staining of MYCN Immunohistochemistry Predicts a Poor Prognosis in MYCN Non-Amplified Neuroblastoma.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)6
- Pediatric radiation enteritis with intestinal failure: A case report and literature review.
- [Neuroblastoma with the expression of cytokeratin: report of a case].
- Comparative Analysis of Flow Cytometry and Cytomorphology for Neuroblastoma Cell Detection in Effusion and Bone Marrow Specimens.
- The antitumor effect of static and extremely low frequency magnetic fields against nephroblastoma and neuroblastoma.
- A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report.
- Autologous cord blood transplantation for metastatic neuroblastoma.
All its trials on ClinicalTrials.gov, any status3
- Construction and Validation of an Intelligent Ultrasound Diagnostic System for the Spectrum of Neuroblastoma in Children
- Risk Model for Metastasis Detection of Neuroblastoma
- Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病Led 5 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 2.2%.
- Open trials led
- 0
- recruiting or about to
2 hospitals in Hangzhou for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
- Phase
- Phase 2
- Started
- 2022-01
- Registry
- NCT05334823
Age 3 years to 21 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou
- RecruitingA Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
- Phase
- Phase 1/Phase 2
- Started
- 2022-11
- Registry
- NCT05579132
Age 2 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChengdu, Chongqing, Guangzhou, Hangzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led5
- Multi-courses of blinatumomab combined with reduced dose chemotherapy has been successfully used in chemo-intolerant middle to high-risk pediatric B-ALL patients with invasive fungal disease.
- Leukemia Burden Impacts the Efficacy and Toxicity of Blinatumomab in Pediatric B-Cell Acute Lymphoblastic Leukemia.
- The impact of asparaginase phenotype-related single nucleotide polymorphisms on prognosis in pediatric B-cell precursor acute lymphoblastic leukemia.
- Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics.
- The effectiveness of blinatumomab in clearing measurable residual disease in pediatric B-cell acute lymphoblastic leukemia patients detected by next-generation sequencing.
All its trials on ClinicalTrials.gov, any status5
- Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
- MRD Detection by NGS in Pediatric B-ALL
- A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
- A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
- A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Blood disorders
Aplastic anaemia
再生障碍性贫血Led 2 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Hangzhou for aplastic anaemia63 hospitals in China for aplastic anaemia
No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led2
- Reduced regulatory effects of bone marrow-derived mesenchymal stem cells on activated T lymphocytes and Th1/Th2 cytokine secretion in children with aplastic anemia.
- Efficacy and safety of immunosuppressive therapy with or without eltrombopag in pediatric patients with acquired aplastic anemia: A Chinese retrospective study.
Chinese-language papers (not in the count)2
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led 8 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 2.0%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Hangzhou for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led8
- Interferon-gamma and C-X-C motif chemokine ligand 9, which is better for haemophagocytic lymphohistiocytosis diagnosis and monitoring?
- High Epstein-Barr Virus DNA Load in T Cells Predicts Hemophagocytic Lymphohistiocytosis.
- Comparative study of biomarkers for the early identification of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in infectious mononucleosis.
- Simple Evaluation of Clinical Situation and Subtypes of Pediatric Hemophagocytic Lymphohistiocytosis by Cytokine Patterns.
- Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report.
- Fulminant cytokine release syndrome in a paediatric patient with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis receiving nivolumab treatment.
- Diagnostic value of red blood cell distribution width, platelet distribution width, and red blood cell distribution width to platelet ratio in children with hemophagocytic lymphohistiocytosis.
- Familial hemophagocytic lymphohistiocytosis in a neonate: Case report and literature review.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status1
More papers found outside PubMed (not counted)4
- Evaluating absolute neutrophil count, IL-6, and IL-10 as rapid diagnostic tools for bacterial infections and septic shock in pediatric leukemia patients
- Evaluation of the Efficacy of PD-1 Monoclonal Antibody Combined with L-DEP Regimen in Children with Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis and Chronic Active EBV Infection
- Risk and Response Adapted Treatment Based on Cytokine and Clinical Condition in Hemophagocytic Lymphohistiocytosis
- Low ratio of IL-10 to IFN-γ and Low IL-10 level indicate good prognosis in Salmonella enterica serovar Typhimurium triggered secondary hemophagocytic lymphohistiocytosis: a case report and literature review
Blood disorders
Haemophilia A
血友病 ALed no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Hangzhou for haemophilia A160 hospitals in China for haemophilia A
No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status6
- Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A
- Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
- A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
- A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors
- A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors
- A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A
Blood disorders
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Hangzhou for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura
No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Myasthenia gravis
重症肌无力Led 1 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.2%.
- Open trials as a site
- 0
- led by another institution
6 hospitals in Hangzhou for myasthenia gravis93 hospitals in China for myasthenia gravis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingA Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis
- Phase
- N/A
- Started
- 2026-03
- Registry
- NCT07298928
Age Not stated to 18 years (registered criteria)
Led by Children's Hospital, Zhejiang University School of MedicineHangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led1
All its trials on ClinicalTrials.gov, any status1
Other diseases
Biliary atresia
胆道闭锁Led 2 of the 214 English-language PubMed papers on biliary atresia with an author in mainland China, 2021–2025: 0.9%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Hangzhou for biliary atresia28 hospitals in China for biliary atresia
No open trial on biliary atresia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status3
- Kasai Portoenterostomy Timing and Outcomes in Biliary Atresia
- Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy
- Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Hangzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Chinese-language papers (not in the count)1
Other diseases
Spinal muscular atrophy
脊髓性肌萎缩症Led 2 of the 55 English-language PubMed papers on spinal muscular atrophy with an author in mainland China, 2021–2025: 3.6%.
- Open trials led
- 0
- recruiting or about to
1 hospital in Hangzhou for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
- Phase
- Phase 1/Phase 2
- Started
- 2026-07
- Registry
- NCT07554924
Age Not stated to 180 days (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
Chinese-language papers (not in the count)3
- [Nusinersen in the treatment of 4 children with presymptomatic spinal muscular atrophy].
- Efficacy and safety of salbutamol in treatment of children with later-onset spinal muscular atrophy.
- [Clinical follow-up analysis of nusinersen in the disease-modifying treatment of pediatric spinal muscular atrophy].
All its trials on ClinicalTrials.gov, any status6
- Chinese Regional Spinal Muscular Atrophy Patient Registration Study
- A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
- Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1
- Pediatric Spinal Muscular Atrophy (SMA) China Registry
- A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)
- Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
Other diseases
Fabry disease
法布雷病Led 2 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 2.7%.
- Open trials as a site
- 0
- led by another institution
7 hospitals in Hangzhou for Fabry disease85 hospitals in China for Fabry disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingEvaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT06539624
Age 7 years to Not stated (registered criteria)
Led by Children's Hospital, Zhejiang University School of Medicine; 1 listed hospital as study siteHangzhou, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
Chinese-language papers (not in the count)4
- [Clinical observation and anti-drug antibody monitoring of enzyme replacement therapy in children with Fabry disease].
- [Genotype-phenotype analysis of Fabry disease caused by GLA gene variation in a pedigree].
- [A child of Fabry disease with appendicitis as initial symptom and family screening].
- [Clinical features and enzyme replacement therapy in 4 children with Fabry disease].
All its trials on ClinicalTrials.gov, any status4
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Hangzhou for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)1
Other diseases
Alport syndrome
Alport 综合征Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Hangzhou for Alport syndrome60 hospitals in China for Alport syndrome
No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status1
Other diseases
IgA nephropathy
IgA 肾病Led 7 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.9%.
- Open trials as a site
- 0
- led by another institution
15 hospitals in Hangzhou for IgA nephropathy346 hospitals in China for IgA nephropathy
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingAllogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
- Phase
- Early phase 1
- Started
- 2026-04
- Registry
- NCT07507201
Age 3 years to Not stated (registered criteria)
Led by Children's Hospital, Zhejiang University School of MedicineHangzhou
- RecruitingCD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
- Phase
- Early phase 1
- Started
- 2026-05
- Registry
- NCT07586267
Age 3 years to Not stated (registered criteria)
Led by Children's Hospital, Zhejiang University School of MedicineHangzhou
- RecruitingAnti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
- Phase
- Early phase 1
- Started
- 2025-01
- Registry
- NCT06792799
Age 3 years to Not stated (registered criteria)
Led by Children's Hospital, Zhejiang University School of MedicineHangzhou
- RecruitingCAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
- Phase
- Phase 1
- Started
- 2025-12
- Registry
- NCT07305116
Age 3 years to Not stated (registered criteria)
Led by Children's Hospital, Zhejiang University School of MedicineHangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led7
- Efficacy and safety of telitacicept in the treatment of pediatric IgA nephropathy: a retrospective study.
- Serum cytokine profiles in children with IgA vasculitis with nephritis.
- Successful outcome of a refractory IgA vasculitis nephritis in children treated with telitacicept.
- Risk Factors of Histopathological Crescent Formation in Pediatric IgA Vasculitis Nephritis.
- Telitacicept as a BAFF/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis.
- Single-cell RNA sequencing of pediatric renal tissues revealed the potential relationship between immunoglobulin A nephropathy and immunoglobulin A vasculitis with nephritis.
- Primary IgA nephropathy with nephrotic-range proteinuria in Chinese children.
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status5
- Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
- CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
- CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
- Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
- RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
Other diseases
Niemann–Pick disease type C
尼曼-匹克病 C 型Led no English-language PubMed papers on Niemann–Pick disease type C in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Hangzhou for Niemann–Pick disease type C15 hospitals in China for Niemann–Pick disease type C
No open trial on Niemann–Pick disease type C lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Other diseases
Congenital diaphragmatic hernia
先天性膈疝Led no English-language PubMed papers on congenital diaphragmatic hernia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Hangzhou for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia
No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Hirschsprung disease
先天性巨结肠Led 4 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 2.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Hangzhou for Hirschsprung disease82 hospitals in China for Hirschsprung disease
No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Developments and prospects of robotic-assisted surgery in the treatment of pediatric Hirschsprung's disease: a comprehensive review.
- Robot-assisted abdominal surgery in children less than 5 months of age: retrospective cohort study.
- Comparation of robotic-assisted surgery and laparoscopic‑assisted surgery in children with Hirschsprung's disease: a single-centered retrospective study.
- Neuroimmune regulation in Hirschsprung's disease associated enterocolitis.
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status1
Other diseases
Leber hereditary optic neuropathy
Leber 遗传性视神经病变Led 4 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 7.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Hangzhou for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy
No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Abnormal morphology and function in retinal ganglion cells derived from patients-specific iPSCs generated from individuals with Leber's hereditary optic neuropathy.
- Leber's hereditary optic neuropathy-associated ND6 14484T > C mutation caused pleiotropic effects on the complex I, RNA homeostasis, apoptosis and mitophagy.
- Mitochondrial tRNA variants in 811 Chinese probands with Leber's hereditary optic neuropathy.
- Assocation Between Leber's Hereditary Optic Neuropathy and MT-ND1 3460G>A Mutation-Induced Alterations in Mitochondrial Function, Apoptosis, and Mitophagy.
Earlier papers (2016–2020)8
- Complex I mutations synergize to worsen the phenotypic expression of Leber's hereditary optic neuropathy.
- PRICKLE3 linked to ATPase biogenesis manifested Leber's hereditary optic neuropathy.
- [Clinical practice guidelines for Leber's hereditary optic neuropathy].
- Contribution of mitochondrial ND1 3394T>C mutation to the phenotypic manifestation of Leber's hereditary optic neuropathy.
- Leber's hereditary optic neuropathy (LHON)-associated ND5 12338T > C mutation altered the assembly and function of complex I, apoptosis and mitophagy.
- Leber's hereditary optic neuropathy caused by a mutation in mitochondrial tRNAThr in eight Chinese pedigrees.
- Leber's hereditary optic neuropathy is potentially associated with a novel m.5587T>C mutation in two pedigrees.
- Biochemical evidence for a mitochondrial genetic modifier in the phenotypic manifestation of Leber's hereditary optic neuropathy-associated mitochondrial DNA mutation.
Other diseases
Majeed syndrome
Majeed 综合征Led 1 of the 3 English-language PubMed papers on Majeed syndrome with an author in mainland China, 2021–2025: 33.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Hangzhou for Majeed syndrome7 hospitals in China for Majeed syndrome
No open trial on Majeed syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Getting in touch
Name card to show staff or a driver
浙江大学医学院附属儿童医院
Children's Hospital, Zhejiang University School of Medicine
杭州
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Children's Hospital; Children's Hospital of Zhejiang University